Viracta Therapeutics, Inc.

NASDAQ:VIRX

0.17 (USD) • At close January 14, 2025
Bedrijfsnaam Viracta Therapeutics, Inc.
Symbool VIRX
Munteenheid USD
Prijs 0.17
Beurswaarde 6,752,540
Dividendpercentage 0%
52-weken bereik 0.13 - 1.31
Industrie Biotechnology
Sector Healthcare
CEO Mr. Mark Andrew Rothera
Website https://www.viracta.com

An error occurred while fetching data.

Over Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of

Vergelijkbare Aandelen

Journey Medical Corporation logo

Journey Medical Corporation

DERM

3.73 USD

Augmedix, Inc. logo

Augmedix, Inc.

AUGX

2.345 USD

BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp.

BCTX

0.39 USD

Centogene N.V. logo

Centogene N.V.

CNTG

0.325 USD

Eyenovia, Inc. logo

Eyenovia, Inc.

EYEN

0.086 USD

Galectin Therapeutics Inc. logo

Galectin Therapeutics Inc.

GALT

1.15 USD

Minerva Surgical, Inc. logo

Minerva Surgical, Inc.

UTRS

0 USD

HCW Biologics Inc. logo

HCW Biologics Inc.

HCWB

0.342 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)